» Articles » PMID: 24897998

Recombinant IFN-α2a-NGR Exhibits Higher Inhibitory Function on Tumor Neovessels Formation Compared with IFN-α2a in Vivo and in Vitro

Overview
Journal Cytotechnology
Specialties Biotechnology
Genetics
Date 2014 Jun 6
PMID 24897998
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

We previously reported that NGR-fused IFN-α2a (IFN-α2a-NGR) exhibited similar biological activities with native IFN-α2a and was well-tolerated in mice, rats and monkeys. In the current study, we evaluated the mechanisms of this fusion protein on angiogenesis and tumor formation. Our data indicated that IFN-α2a-NGR has the ability to target tumor blood vessels while preserving the original function of native IFN-α2a. IFN-α2a-NGR was found to be concentrated in the tumor tissues, particularly around the vessel areas. In contrast to IFN-α2a, IFN-α2a-NGR significantly decreased microvessel density and increased the apoptosis of vascular endothelial cells. IFN-α2a-NGR also decreased the expression of VEGF and bFGF in tumor cells. Significant inhibition of invasion, migration, tube formation and induction of apoptosis of endothelial cells were observed in IFN-α2a-NGR-treated group. In conclusion, results from in vitro and in vivo experiments indicate that IFN-α2a-NGR is a promising anti-angiogenic agent with greater therapeutic efficacy than IFN-α2a.

Citing Articles

Research advances in peptide‒drug conjugates.

Gong L, Zhao H, Liu Y, Wu H, Liu C, Chang S Acta Pharm Sin B. 2023; 13(9):3659-3677.

PMID: 37719380 PMC: 10501876. DOI: 10.1016/j.apsb.2023.02.013.

References
1.
Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A . Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000; 18(11):1185-90. DOI: 10.1038/81183. View

2.
von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K . Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003; 95(6):437-48. DOI: 10.1093/jnci/95.6.437. View

3.
Von Hoegen P, Zawatzky R, Schirrmacher V . Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta. Cell Immunol. 1990; 126(1):80-90. DOI: 10.1016/0008-8749(90)90302-8. View

4.
Curnis F, Sacchi A, Corti A . Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest. 2002; 110(4):475-82. PMC: 150417. DOI: 10.1172/JCI15223. View

5.
Rios A, Mansell P, Newell G, Reuben J, Hersh E, Gutterman J . Treatment of acquired immunodeficiency syndrome--related Kaposi's sarcoma with lymphoblastoid interferon. J Clin Oncol. 1985; 3(4):506-12. DOI: 10.1200/JCO.1985.3.4.506. View